Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.
2.

Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.

5.

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Guazzi M, Vicenzi M, Arena R, Guazzi MD.

Circulation. 2011 Jul 12;124(2):164-74. doi: 10.1161/CIRCULATIONAHA.110.983866. Epub 2011 Jun 27.

6.

Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.

Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N.

J Card Fail. 2008 Apr;14(3):189-97. doi: 10.1016/j.cardfail.2007.11.006.

PMID:
18381181
7.

Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?

Amin A, Mahmoudi E, Navid H, Chitsazan M.

Congest Heart Fail. 2013 Mar-Apr;19(2):99-103. doi: 10.1111/chf.12008. Epub 2012 Dec 12.

8.

Long-term use of sildenafil in the therapeutic management of heart failure.

Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD.

J Am Coll Cardiol. 2007 Nov 27;50(22):2136-44. Epub 2007 Nov 13.

9.

Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.

Botha P, Parry G, Dark JH, Macgowan GA.

J Heart Lung Transplant. 2009 Jul;28(7):676-82. doi: 10.1016/j.healun.2009.04.013. Epub 2009 May 13.

PMID:
19560695
10.

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Jan 6;150(1):63. Ann Intern Med. 2009 Sep 15;151(6):435.

PMID:
18936500
11.

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S.

Circulation. 2002 May 21;105(20):2398-403.

12.

Sildenafil improves the alveolar-capillary function in heart failure patients.

Bussotti M, Montorsi P, Amato M, Magini A, Baldassarre D, Tantardini F, Veglia F, Agostoni P.

Int J Cardiol. 2008 May 7;126(1):68-72. Epub 2007 May 8.

PMID:
17490765
13.

Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure.

Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Jan 2;115(1):59-66. Epub 2006 Dec 18.

14.

Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension.

Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL.

Circulation. 2003 Oct 28;108(17):2066-9. Epub 2003 Oct 20.

15.

Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barberà JA.

Am J Respir Crit Care Med. 2010 Feb 1;181(3):270-8. doi: 10.1164/rccm.200907-0988OC. Epub 2009 Oct 29.

PMID:
19875684
16.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group.

N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.

18.

Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil.

Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R.

Int J Cardiol. 2010 Oct 29;144(3):410-2. doi: 10.1016/j.ijcard.2009.03.041. Epub 2009 Mar 28.

PMID:
19329196
19.

A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.

Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, Sastry BK, Pulido T, Layton GR, Serdarevic-Pehar M, Wessel DL.

Circulation. 2012 Jan 17;125(2):324-34. doi: 10.1161/CIRCULATIONAHA.110.016667. Epub 2011 Nov 29.

20.

Effects of pulmonary vasodilator therapy on ventilatory efficiency during exercise in adults with Eisenmenger syndrome.

Yang-Ting S, Aboulhosn J, Sun XG, Child JS, Sietsema KE.

Congenit Heart Dis. 2011 Mar-Apr;6(2):139-46. doi: 10.1111/j.1747-0803.2011.00490.x. Epub 2011 Mar 21.

PMID:
21418531

Supplemental Content

Support Center